
Unique immunotherapy extends survival in advanced NSCLC
Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC). The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More















